Effect of Injectable Platelet-Rich Fibrin (i-PRF) in Initial Treatment of Chronic Periodontitis (EIPRFITCP)

University of Belgrade

Status and phase: Completed; Phase 4

Conditions: Periodontitis

Treatments: Drug: SRP + Injectable Platelet-Rich Fibrin; Drug: SRP + placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT04178590

UBelgrade 783/2

Details and patient eligibility

About

Current treatments of periodontitis have limited efficacy since they fail to suppress microorganisms satisfactorily over time. The aim of present study was to investigate whether there are differences between initial treatment of chronic periodontitis (SRP) and SRP in conjunction with injectable platelet-rich fibrin (i-PRF) application.

Full description

Current treatments of periodontitis have limited efficacy since they fail to suppress microorganisms satisfactorily over time. The aim of present study was to investigate whether there are differences between initial treatment of chronic periodontitis (SRP) and SRP in conjunction with injectable platelet-rich fibrin (i-PRF) application.

Thirty patients with chronic periodontitis who had at least two sites with perriodontal pocket depth (PPD) ≥ 4 mm on contralateral side will be involved in the study. Using a split-mouth design, patients will be treated with SRP + I-PRF -(test group) or SRP only-(control group). Gingival crevicular fluid (GCF) and subgingival plaque will be collected with paper points (DentsplyMaillefer, Tulsa, Oklahoma, USA) at baseline and 1, 3 and 6 months after the treatment. The presence and concentrations of Aggregatibacter actinomycetemcomitans (Aa), Porphyromonas gingivalis (Pg), Prevotella intermedia (Pi) and Tannerella forsythia(Tf) will be analyzed by real-time polymerase chain reaction (qPCR). Periodontal parameters, including bleeding on probing (BOP), probing pocket depth (PPD) and the clinical attachment level (CAL), will be recorded on both sides, as well as concentration of TNF-alpha (tumor necrosis factor alpha), ALP(alkaline phosphatase) and MMP-8 (matrix-metalloproteinase-8).

Enrollment: 32 patients

Sex: All

Ages: 20 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• A minimum of 6 teeth per quadrant;

  • A minimum of 2 teeth in each quadrant with a probing depth (PD) ≥5 mm;
  • Bleeding on probing (BOP) had to be at ≥40% tooth sites;
  • No involvement of furcation;
  • Good general health.

Exclusion criteria

• Periodontal therapy within last 12 months;

  • Having surgical therapy;
  • Use of antibiotics over the last 6 months;
  • Ongoing drug therapy that might have an impact on the clinical signs and symptoms of periodontitis;
  • Pregnancy or nursing;
  • Current and former smokers.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Single Blind

---

32 participants in 2 patient groups, including a placebo group

SRP + Injectable Platelet-Rich Fibrin

Experimental group

Description:

Scaling and root planing in conjunction with Injectable Platelet-Rich Fibrin

Treatment:

Drug: SRP + Injectable Platelet-Rich Fibrin

SRP + placebo

Placebo Comparator group

Description:

Scaling and root planing in conjunction with saline

Treatment:

Drug: SRP + placebo